CUTTING-EDGE MRD DETECTION FOR EVERY POINT OF PATIENT CARE
Leading cancer centers standardize on clonoSEQ®, using it to precisely identify minimal residual disease (MRD) at the DNA sequence level. When integrated into routine clinical practice, clonoSEQ is an essential part of advancing patient care in lymphoid malignancies.